Candel Therapeutics Stock Investor Sentiment

CADL Stock  USD 8.98  0.38  4.42%   
About 50% of Candel Therapeutics' institutional investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Candel Therapeutics suggests that some traders are interested. Candel Therapeutics' investing sentiment shows overall attitude of investors towards Candel Therapeutics.
  

Candel Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Candel Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
55.6%
55.3%
58.3%
53.6%
53.4%
58.3%
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Candel Therapeutics Maximum Pain Price Across April 17th 2025 Option Contracts

Candel Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Candel Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Candel Therapeutics' options.
Calls PricePuts Price
2 days ago at thelincolnianonline.com         
Candel Therapeutics Price Target Raised to 25.00
news
3 days ago at simplywall.st         
Insiders Enjoy US1.3m Return After Buying Candel Therapeutics Stock
Simply Wall St News at Macroaxis
3 days ago at finance.yahoo.com         
Institutional investors in Candel Therapeutics, Inc. see US153m decrease in market cap last week, al...
Yahoo News
few days ago at gurufocus.com         
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 ...
Gurufocus Stories at Macroaxis
over a week ago at thelincolnianonline.com         
Candel Therapeutics Earns Buy Rating from Analysts at Canaccord Genuity Group
news
over a week ago at www.macroaxis.com         
Disposition of 10582 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 12.02 subject to R...
Macroaxis News
over a week ago at talkmarkets.com         
Major Indexes Falter Dow Drops Over 550 Points
news
over a week ago at benzinga.com         
This GE Vernova Analyst Begins Coverage On A Bullish Note Here Are Top 5 Initiations For Wednesday
benzinga news
over two weeks ago at gurufocus.com         
Baker Bros. Advisors LP Acquires Significant Stake in Candel Therapeutics Inc.
Gurufocus Stories at Macroaxis
over two weeks ago at news.google.com         
Trend Tracker for - Stock Traders Daily
Google News at Macroaxis
over two weeks ago at www.macroaxis.com         
Acquisition by Barone Francesca of 115000 shares of Candel Therapeutics at 8.55 subject to Rule 16b-...
Macroaxis News
over two weeks ago at www.macroaxis.com         
Disposition of 31335 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 8.61 subject to Ru...
Macroaxis News
over three weeks ago at gurufocus.com         
FMR LLCs Strategic Acquisition of Candel Therapeutics Shares
Gurufocus Stories at Macroaxis
over three weeks ago at gurufocus.com         
FMR LLCs Strategic Acquisition of Candel Therapeutics Shares
Gurufocus Stories at Macroaxis
over a month ago at finance.yahoo.com         
Insider Stock Buying Of Candel Therapeutics Delivers Return On US3.00m Investment
Yahoo News
Far too much social signal, news, headlines, and media speculation about Candel Therapeutics that are available to investors today. That information is available publicly through Candel media outlets and privately through word of mouth or via Candel internal channels. However, regardless of the origin, that massive amount of Candel data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Candel Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Candel Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Candel Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Candel Therapeutics alpha.

Candel Therapeutics Performance against Dow Jones

 Price Growth (%)  
JavaScript chart by amCharts 3.21.15123456789101112131415161718192021Dec2025Feb 050100150200
JavaScript chart by amCharts 3.21.15Candel Therapeutics Candel Therapeutics Dividend Benchmark Dow Jones Industrial
       Timeline  
1
Disposition of 20000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 4.46 subject to Rule 16b-3
12/04/2024
2
Disposition of 1800 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 6.85 subject to Rule 16b-3
12/06/2024
3
Acquisition by Benz Edward J. Jr of 14240 shares of Candel Therapeutics at 5.71 subject to Rule 16b-3
12/10/2024
4
Disposition of 200000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 10.04 subject to Rule 16b-3
12/12/2024
5
Paul B. Manning Buys 1,250,000 Shares of Candel Therapeutics, Inc. Stock
12/20/2024
6
Disposition of 50000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 8.52 subject to Rule 16b-3
12/23/2024
7
Disposition of 50000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 8.82 subject to Rule 16b-3
12/24/2024
8
Disposition of 50000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 9.01 subject to Rule 16b-3
12/26/2024
9
Disposition of 50000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 8.85 subject to Rule 16b-3
12/27/2024
10
Disposition of 9884 shares by Charles Schoch of Candel Therapeutics at 6.4726 subject to Rule 16b-3
01/03/2025
11
Institutions profited after Candel Therapeutics, Inc.s market cap rose US41m last week but retail investors profited the most
01/06/2025
12
Acquisition by Nguyen Diem of 14240 shares of Candel Therapeutics at 5.71 subject to Rule 16b-3
01/07/2025
13
Candel therapeutics CMO sells 88,749 in stock - Investing.com
01/10/2025
14
Disposition of 10428 shares by Nichols William Garrett of Candel Therapeutics at 7.225 subject to Rule 16b-3
01/15/2025
15
FMR LLCs Strategic Acquisition of Candel Therapeutics Shares
02/07/2025
16
Disposition of 31335 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 8.61 subject to Rule 16b-3
02/10/2025
17
Acquisition by Barone Francesca of 115000 shares of Candel Therapeutics at 8.55 subject to Rule 16b-3
02/12/2025
18
Trend Tracker for - Stock Traders Daily
02/13/2025
19
Major Indexes Falter Dow Drops Over 550 Points
02/20/2025
20
Disposition of 10582 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 12.02 subject to Rule 16b-3
02/21/2025
21
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 ...
02/25/2025
When determining whether Candel Therapeutics is a strong investment it is important to analyze Candel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Candel Therapeutics' future performance. For an informed investment choice regarding Candel Stock, refer to the following important reports:
Check out Candel Therapeutics Hype Analysis, Candel Therapeutics Correlation and Candel Therapeutics Performance.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.73)
Revenue Per Share
0.001
Return On Assets
(0.52)
Return On Equity
(4.81)
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
News Freq…Investor S…